School of Medicine, Belgrade University, Belgrade, Serbia; Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia.
School of Medicine, Belgrade University, Belgrade, Serbia; Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia.
Int J Cardiol. 2019 Feb 1;276:130-135. doi: 10.1016/j.ijcard.2018.08.018. Epub 2018 Aug 11.
Reliable identification of atrial fibrillation (AF) patients more likely to be AF-free long-term post-single catheter ablation (CA) would facilitate appropriate risk communication to patients. We validated the recently proposed MB-LATER score for prediction of late recurrences of AF (LRAF) post-CA.
Patients who underwent CA for symptomatic AF refractory to ≥1 antiarrhythmic drugs at the Johns Hopkins Hospital, Baltimore, between March 2003 and December 2015, for whom ≥1-year post-CA follow-up data were available, were enrolled.
Of 226 patients (median age 58.5 years [IQR: 52.0-65.0], 163 males [72.1%], 142 [62.8%] with paroxysmal AF), LRAF occurred in 133 patients (58.8%) during a median 2-year follow-up (IQR: 1.1-4.1). The mean MB-LATER score was significantly higher in patients with versus those without LRAF (2.4 ± 1.2 vs. 1.9 ± 1.3, p = 0.002) and showed modest but significant predictive ability for LRAF (AUC: 0.62 [95% CI: 0.54-0.69], p = 0.003). A score cut-off value of >2 showed the best predictive ability for LRAF (70.4% [61.5-77.9]), with modest sensitivity (42.9% [34.3-51.7]) and specificity (74.2% [64.1-82.7]). Kaplan-Meyer survival free from AF was significantly better for patients with a MB-LATER score of ≤2 than for those with a score of >2 (log-rank p = 0.005).
In our study, the MB-LATER score showed a significant but modest predictive ability for LRAF post-AF ablation. Further prospective validation is needed to better define the potential role of the MB-LATER score in patient selection and treatment decision-making post-AF ablation.
可靠地识别出更有可能在单次导管消融(CA)后长期无房颤(AF)的房颤(AF)患者,将有助于向患者进行适当的风险沟通。我们验证了最近提出的用于预测 CA 后晚期房颤复发(LRAF)的 MB-LATER 评分。
在巴尔的摩的约翰霍普金斯医院,2003 年 3 月至 2015 年 12 月,对因抗心律失常药物治疗无效而接受 CA 治疗的症状性 AF 患者进行了这项研究,共纳入 226 名患者(中位年龄 58.5 岁[IQR:52.0-65.0],163 名男性[72.1%],142 名[62.8%]为阵发性 AF),在中位 2 年的随访期间(IQR:1.1-4.1),133 名患者(58.8%)发生了 LRAF。MB-LATER 评分在发生 LRAF 患者中明显高于未发生 LRAF 患者(2.4±1.2 比 1.9±1.3,p=0.002),并且对 LRAF 具有适度但显著的预测能力(AUC:0.62[95%CI:0.54-0.69],p=0.003)。评分>2 的截断值对 LRAF 具有最佳的预测能力(70.4%[61.5-77.9]),具有适度的敏感性(42.9%[34.3-51.7])和特异性(74.2%[64.1-82.7])。MB-LATER 评分≤2 的患者 AF 无复发的 Kaplan-Meier 生存曲线显著优于评分>2 的患者(log-rank p=0.005)。
在我们的研究中,MB-LATER 评分对 AF 消融后 LRAF 具有显著但适度的预测能力。需要进一步的前瞻性验证,以更好地确定 MB-LATER 评分在 AF 消融后患者选择和治疗决策中的潜在作用。